Reduced mortality rate and shorter time for clinical improvement upon Remdesivir treatment
This retrospective comparative effectiveness research study was conducted from March 4 to August 29, 2020, in a 5-hospital health system
Tag: remdesivir
Remdesivir-Ivermectin combination displays synergistic interaction with improved in vitro antiviral activity against SARS-CoV-2
Drug combination strategies of repurposed drugs offer a number of advantages to monotherapies including the potential to achieve greater efficacy,
NIH funds study to evaluate remdesivir for COVID-19 in pregnancy
A new study funded by the National Institutes of Health will evaluate the effects of remdesivir in pregnant women who
Reviews on remdesivir in Covid-19 treatment
Remdesivir (GS-5734; Gilead Sciences Inc., US) is an investigational nucleoside analog that acts as a competitive inhibitor of viral RNAdependent
RotaChrom Technologies Partners With Cyclolab to Increase Production of COVID-19 Treatment
RotaChrom Technologies, the developer of the world’s first industrial-scale Centrifugal Partition Chromatography (CPC) technology platform, announced today the launch of
Renal and liver injury following the treatment of covid-19 by remdesivir
Remdesivir initially was intravenously administrated to treat the Ebola disease however right now it has been administered to treat COVID-19
Dendrimer-based formulation of remdesivir
Current formulations of remdesivir are required to be administered intravenously due to the drug’s low solubility, with each infusion taking
Remdesivir dry powder inhalation formulation, pharmacokinetic study in hamsters
Currently, remdesivir is only available as a lyophilized powder for reconstitution and intravenous53 infusion and concentrate solution for dilution and
FIRST EXPERIMENTS IN SPACE FOR COVID-19 DRUG RESEARCH
The COVID-19 pandemic has generated new and urgent challenges in drug discovery and development. Veklury®, a remdesivir-based medicament invented by
Lilly’s baricitinib/remdesivir combo lowers recovery time in hospitalised COVID-19 patients
Eli Lilly has unveiled promising new data from a study investigating the efficacy of baricitinib when combined with with Gilead’s